Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
In HIV-infected patients failing therapy, with HIV RNA >1000 copies/mL and documented resistance to at least 1 drug in each of the 3 classes of licensed oral antiretrovirals (ARTs) (Nucleoside Reverse Transcriptase Inhibitors [NRTIs], Non-Nucleoside Reverse Transcriptase Inhibitors [NNRTIs], and Protease Inhibitors [PIs]): (1) Evaluate the antiretroviral activity of MK-0518 400 mg b.i.d. compared to placebo, both in combination with Optimized Background Therapy (OBT), as measured by proportion of patients achieving HIV RNA <400 copies/mL at Week 16. (2) Evaluate the safety and tolerability of MK-0518 400 mg b.i.d. compared to placebo, both in combination with OBT, assessed by review of the accumulated safety data.
Critère d'inclusion
- Unspecified human immuno-deficiency virus [HIV] disease